0001193125-23-276030.txt : 20231113 0001193125-23-276030.hdr.sgml : 20231113 20231113161306 ACCESSION NUMBER: 0001193125-23-276030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 231398854 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 8-K 1 d572144d8k.htm 8-K 8-K
false 0001701108 0001701108 2023-11-13 2023-11-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2023

 

 

SPERO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38266   46-4590683
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

675 Massachusetts Avenue, 14th Floor

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (857) 242-1600

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value   SPRO   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On November 13, 2023, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d)    Exhibits.

 

99.1    Press Release, dated November 13, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 13, 2023     SPERO THERAPEUTICS, INC.
    By:  

/s/ Tamara Joseph

      Tamara Joseph
      Chief Legal Officer
 EX-99.1 2 d572144dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023

Conference call and webcast at 4:30pm ET today

CAMBRIDGE, Mass., November 13, 2023 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.

“Having made substantial progress across our late-stage programs throughout 2023, we look forward to important milestones before year-end,” said Sath Shukla, President, and Chief Executive Officer of Spero. “In our SPR720 program, enrollment for our Phase 2 clinical proof-of-concept trial, evaluating the product in non-tuberculous mycobacterial pulmonary disease, continues to advance. Enrollment of our first patients in the Phase 3 PIVOT-PO clinical trial of tebipenem HBr is expected to begin in the fourth quarter. Further, we expect to file an IND for SPR206, in the fourth quarter of this year, as well, with the goal of conducting a Phase 2 clinical trial in patients with hospital-acquired or ventilator-associated bacterial pneumonia.”

Program Highlights and Upcoming Anticipated Milestones

Tebipenem HBr

 

  •  

Spero received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design and size of PIVOT-PO, a pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP).

 

  •  

PIVOT-PO is a global, randomized, double-blind, pivotal Phase 3 clinical trial of oral tebipenem HBr vs. intravenous (IV) imipenem cilastatin, in hospitalized adult patients with cUTI/AP. Patients will be randomized 1:1 to receive tebipenem HBr (600 mg) orally every six hours, or imipenem cilastatin (500 mg) IV every six hours, for a total of seven to ten days. The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The primary analysis for the trial will be an assessment of non-inferiority (NI) in the microbiological intention-to-treat population, based on a 10% NI margin. The trial is designed to enroll approximately 2,648 patients, with randomization stratified by age, baseline diagnosis (cUTI or AP), and the presence or absence of urinary tract instrumentation. For further details on the trial, refer to clinicaltrials.gov identifier NCT06059846.

 

  •  

Pursuant to its exclusive license agreement with GSK, Spero received a $30 million development milestone payment. Spero is also eligible to receive the following additional milestone/royalty payments under the terms of its license agreement with GSK, conditional upon achievement of certain progression of milestones: (1) up to an additional $120 million in development milestones as the Phase 3 clinical trial progresses; (2) up to $150 million in

 

potential commercial milestones based on first commercial sales; (3) up to $225 million in potential sales-based milestones; and (4) low-single digit to low-double digit (if sales exceed $1 billion) tiered royalties on net product sales of tebipenem HBr in all territories, except Japan and certain other Asian countries.

SPR720

 

  •  

Patient enrollment and dosing continues at 26 active sites in the ongoing Phase 2a clinical trial of SPR720, a potential novel first-line oral therapy for nontuberculous mycobacterial pulmonary disease (NTM-PD). The trial is expected to enroll up to 35 treatment-naïve or treatment-experienced participants with NTM-PD, who do not have treatment-refractory NTM-PD, due to Mycobacterium avium complex. The primary endpoint is evaluating changes in bacterial load in sputum samples from baseline to the end of the 56-day treatment period. Key secondary endpoints include assessments of clinical response, quality of life, pharmacokinetics, and safety and tolerability. Topline data are expected in the second half of 2024. For more information on the trial and its design, see ClinicalTrials.gov identifier NCT05496374.

 

  •  

A paper, titled Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720 (Kevin Winthrop et al), was published online, Oct 20, 2023, in the Expert Review of Anti-infective Therapy. The authors discuss the unmet need in NTM-PD, explaining that current treatment options are limited and the challenges of managing the disease, including length of therapy, poor efficacy, drug intolerance, recurrence, and resistance development. They reviewed data on SPR720 which demonstrated activity against a range of NTM species, including mycobacterium avium complex (MAC) and mycobacterium abscessus (MAB). Encouraging in vitro and pre-clinical data demonstrate that SPR720 is active both alone and in combination with standard-of-care agents, with no evidence of cross-resistance to such agents. The authors concluded that SPR720 should be studied further in the context of a multidrug regimen.

SPR206

 

  •  

Spero is preparing to advance SPR206, a novel, investigational, IV administered next generation polymyxin antibiotic being developed to treat MDR Gram-negative bacterial infections, into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia. Spero expects to submit an Investigational New Drug (IND) application to the FDA to support the Phase 2 clinical trial in the fourth quarter of 2023. Funding of SPR206’s clinical development is currently being provided by the Department of Defense and National Institute of Allergy and Infectious Disease.

  •  

The results from the Phase 1 bronchoalveolar lavage (BAL) study of SPR206 were published in a paper, titled Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects (Keith Rodvold et al), in Antimicrobial Agents and Chemotherapy in June 2023. The results showed SPR206 to be well-tolerated and achieved lung exposures consistent with predicted therapeutic levels when administered three times daily at 100 mg.

 

  •  

A paper, titled Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment (Jon B. Bruss et al), was published in Antimicrobial Agents and Chemotherapy in October 2023. The paper summarizes the results of a study evaluating the safety, tolerability, and pharmacokinetic (PK) of SPR206 with a 100-mg single IV dose in subjects with normal renal function, subjects with varying degrees of renal impairment (RI), and subjects with end-stage renal disease (ESRD) on hemodialysis (HD). SPR206 was generally safe and well-tolerated, and the PK of SPR206 was well characterized in subjects with RI.

Management Update

 

  •  

Effective August 1, 2023, Satyavrat “Sath” Shukla, Spero’s prior Chief Financial Officer and Treasurer, became President and Chief Executive Officer (CEO) of the company, and a member of the Board of Directors, Mr. Shukla succeeded Spero’s prior President and CEO, Ankit Mahadevia, M.D., who became Chairman of the Board of Directors, effective August 1, 2023.

 

  •  

On November 1, 2023, Spero announced the appointment of Esther Rajavelu as the Company’s new Chief Financial Officer and Chief Business Officer. Ms. Rajavelu brings over 20 years of experience in growth strategy, investor relations, financing, and M&A.

Third Quarter 2023 Financial Results

Spero reported a net loss for the third quarter ended September 30, 2023, of $3.2 million or $0.06 per basic and diluted share of common stock, compared to a net loss of $11.7 million or $0.33 per basic and diluted share of common stock reported for the same period in 2022.

Total revenues for the third quarter of 2023 were $25.5 million, compared with revenues of $2.0 million in the third quarter of 2022. Revenues were approximately $23.5 million higher year over year primarily due to $23.2 million in collaboration revenue related to the license agreement with GSK in the third quarter of 2023.

Research and development expenses for the third quarter of 2023 were $16.4 million, compared with $7.4 million of research and development expenses for the same period in 2022. This year over year increase, of approximately $9 million, was primarily due to higher direct costs related to the tebipenem HBr and SPR720 programs. These included increased clinical activity related to the ongoing Phase 2a clinical trial of SPR720 as well as startup clinical activities and increased preclinical activities related to the planned Phase 3 clinical trial of tebipenem HBr.

General and administrative expenses for the third quarter of 2023 were $5.7 million compared with $6.6 million in the same period in 2022. The decrease year over year was primarily a result of decreased personal related costs, as well as lower facility and other related expenses, offset in part by an increase in professional and consultant fees.

An impairment expense was incurred in the third quarter of 2023, as the Company concluded that it no longer had need for commercial manufacturing of tebipenem HBr, provided under a service agreement with Savior Lifetec Corporation. An impairment expense of $5.3 million was recorded as the Company fully impaired the long-term asset, related to the Savior service agreement.

As of September 30, 2023, Spero had cash and cash equivalents of $93.8 million. The Company believes that its cash and cash equivalents will be sufficient to provide funding into the second half of 2025.

For further details on Spero’s financials, including results for the nine-month period ended September 30, 2023, refer to Spero’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (SEC) today.

Conference Call and Webcast

Spero will host a conference call and webcast today at 4:30 p.m. ET. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13741831 or click on this link and request a return call. The conference call will also be webcast live and can be accessed through this website link, and on Spero’s website at www.sperotherapeutics.com on the “Events and Presentations” page under the “Connect” tab. An archived webcast will be available on Spero’s website for 30 days following the presentation.

Tebipenem HBr Research Support

Select tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

Government Agency Research Support

The views expressed in this press release are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Department of Defense

Select SPR206 studies are supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. W81XWH 19 1 0295. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

National Institute of Allergy and Infectious Disease

Select SPR206 studies have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00022.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

 

  •  

Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

 

  •  

Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.

 

  •  

Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

For more information, visit www.sperotherapeutics.com

Forward Looking Statements

This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, as well as the regulatory path forward for tebipenem HBr and potential FDA approval, the potential commercialization of tebipenem HBr and its future value, the potential receipt of milestone payments and royalties on future sales under the GSK license agreement, and Spero’s cash runway. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether tebipenem HBr, SPR720 and SPR206 will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero’s need for additional funding; the ability to commercialize Spero’s product candidates, if approved; Spero’s ability to retain key personnel; Spero’s ongoing leadership transitions; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

Ted Jenkins

Vice President, Investor Relations and Strategic Finance

IR@sperotherapeutics.com

(617) 798-4039

Media Inquiries:

Lora Grassilli, Health Media Relations

Zeno Group

lora.grassilli@zenogroup.com

646-932-3735

Spero Therapeutics, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands)

(Unaudited)

 

     September 30,
2023		      December 31,
2022		  

Cash, cash equivalents and marketable securities

    $ 93,825      $ 109,107  

Other assets

      13,276        15,695  
  

 

 

     

 

 

  

Total assets

    $ 107,101      $ 124,802  
  

 

 

     

 

 

  

Total liabilities

      53,396        48,868  

Total stockholder’s equity

      53,705        75,934  
  

 

 

     

 

 

  

Total liabilities and stockholders’ equity

    $ 107,101      $ 124,802  
  

 

 

     

 

 

  

Spero Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

     Three Months Ended September 30,     Nine Months Ended September 30,  
     2023     2022     2023     2022  

Revenues:

         

Grant revenue

    $ 2,091     $ 924     $ 5,349     $ 3,843  

Collaboration revenue

      23,382       1,082       24,910     $ 2,225  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total revenues

      25,473       2,006       30,259       6,068  

Operating expenses:

         

Research and development

      16,393       7,360       34,883       32,504  

General and administrative

      5,708       6,632       19,121       29,988  

Impairment of long-term asset

      5,306       —         5,306       —    

Restructuring

      —         (152 )      —         11,697  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      27,407       13,840       59,310       74,189  
  

 

 

    

 

 

    

 

 

    

 

 

  

Loss from operations

      (1,934 )      (11,834 )      (29,051 )      (68,121 ) 

Other income (expense)

      940       159       2,877       (5,065 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss before income taxes

      (994 )      (11,675 )      (26,174 )      (73,186 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Income tax expense

      (2,211 )      —         (2,211 )      —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (3,205 )    $ (11,675 )    $ (28,385 )    $ (73,186 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss attributable to common shareholders of Spero Therapeutics, Inc.

    $ (3,205 )    $ (11,675 )    $ (28,385 )    $ (73,186 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share attributable to common shareholders per share, basic and diluted

    $ (0.06 )    $ (0.33 )    $ (0.54 )    $ (2.16 ) 

Weighted average shares outstanding, basic and diluted:

      52,710,280       35,882,076       52,603,709       33,834,198  
 EX-101.SCH 3 spro-20231113.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 spro-20231113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 spro-20231113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 13, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001701108
Document Type 8-K
Document Period End Date Nov. 13, 2023
Entity Registrant Name SPERO THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38266
Entity Tax Identification Number 46-4590683
Entity Address, Address Line One 675 Massachusetts Avenue
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (857)
Local Phone Number 242-1600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol SPRO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d572144d8k_htm.xml IDEA: XBRL DOCUMENT 0001701108 2023-11-13 2023-11-13 false 0001701108 8-K 2023-11-13 SPERO THERAPEUTICS, INC. DE 001-38266 46-4590683 675 Massachusetts Avenue 14th Floor Cambridge MA 02139 (857) 242-1600 false false false false Common Stock, $0.001 par value SPRO NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "B@6U799!YDAD! #/ P $P M @ ' $@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" *% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d572144d8k.htm spro-20231113.xsd spro-20231113_lab.xml spro-20231113_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d572144d8k.htm": { "nsprefix": "spro", "nsuri": "http://sperotherapeutics.com/20231113", "dts": { "inline": { "local": [ "d572144d8k.htm" ] }, "schema": { "local": [ "spro-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "spro-20231113_lab.xml" ] }, "presentationLink": { "local": [ "spro-20231113_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-13_to_2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d572144d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-13_to_2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d572144d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://sperotherapeutics.com//20231113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-23-276030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-276030-xbrl.zip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end